ADVERTISEMENT

User Fees

Looking For STARs: US FDA Expands Split Real Time Review Amid Low Supplement Interest

The STAR pilot established in PDUFA VII for efficacy supplements, which was modeled after the popular Real Time Oncology Review program, has not garnered much interest. The agency now is establishing a separate but similar pilot for a small number of original NDAs and BLAs.

US FDA’s New Voucher Fee Reveals Standard, Priority Review Cost Spike

The number of standard and priority reviews also decreased significantly in FY 2023 compared to the previous year, which caused the fee for redeeming a voucher to rise.

US FDA Forecasts Monograph Program Activities As Overhaul Transitions From Construction Phase

Nonbinding forecast, fourth for the program, includes risks associated with codeine-containing cough medicine as a topic FDA will include in ongoing evaluation of GRASE for pediatric cough cold drug products marketed under monograph for cold, cough, allergy, bronchodilator and anti-asthmatic OTC drugs.

US FDA's Slim October User Fee Calendar Brings Some Controversy

Advisory committee concerns cast clouds over Iterum’s oral antibiotic, Intercept’s Ocaliva, and perioperative immuno-oncology regimens, while CSL and Pfizer aim to take their hematology franchises in new directions.

Inflation Continues To Rear Head At US FDA User Fees

Inflation accounted for a larger portion of user fee revenue target increases for fiscal year 2025, compared to previous years, according to a Pink Sheet analysis.

Model-Informed Drug Development Program Could Handle More Requests, But US FDA Needs Funding

FDA is considering allowing MIDD meeting requests to be submitted more often than the current quarterly schedule, but agency must have a plan to deal with the likely increased demand, official says.

Keeping Score In Drug Development And Innovation Game? Look To US FDA As The Referee – Califf

“It's really the elected officials who are making the final determination on what happens. They're really the owners of the teams, you guys in the industry are playing the game we’re refereeing,” FDA Commissioner Robert Califf says at Consumer Healthcare Products Association conference.

Draft US FDA Innovative Manufacturing Strategy Takes On Global Inconsistency

Agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.

Draft US FDA Innovative Manufacturing Strategy Takes On Global Inconsistency

The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.

Generic Drug Sponsors May Discuss Alternative BE Approaches During Pre-ANDA Meetings

Teva requested the change to the draft guidance, arguing that otherwise the meetings would be “completely one-sided conversations.”